Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Buddhist Tzu Chi General Hospital
Sponsor:
Information provided by (Responsible Party):
Hann-Chorng Kuo, Buddhist Tzu Chi General Hospital
ClinicalTrials.gov Identifier:
NCT01824420
First received: April 1, 2013
Last updated: April 3, 2014
Last verified: April 2014
  Purpose

To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB


Condition Intervention Phase
Overactive Bladder
Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD
Drug: Detrusitol 4mg QD
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy

Resource links provided by NLM:


Further study details as provided by Buddhist Tzu Chi General Hospital:

Primary Outcome Measures:
  • Change from Baseline in the Perception of Bladder Condition (PPBC) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the Perception of Bladder Condition (PPBC) at different time points (1 month, 2 months and 3 months). If patients have a PPBC improved by two scales, they are considered as successfully treated, otherwise failed treatment.

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness



Secondary Outcome Measures:
  • Change from Baseline in the Overactive Bladder Symptom Score (OABSS) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the Overactive Bladder Symptom Score (OABSS) at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the urinary sensation scale (USS) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the urinary sensation scale (USS) at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the International Prostate Symptom Score (IPSS) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the International Prostate Symptom Score (IPSS) at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the maximum flow rate (Qmax) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: Yes ]

    Efficacy:

    Change from Baseline in the maximum flow rate (Qmax) at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the voided volume at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: Yes ]

    Efficacy:

    Change from Baseline in the voided volume at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the postvoid residual volume (PVR) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: Yes ]

    Efficacy:

    Change from Baseline in the postvoid residual volume (PVR) at different time points (1 month, 2 months and 3 months).

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the total prostate volume (TPV) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the total prostate volume (TPV) at different time points (1 month, 2 months and 3 months) are evaluated in men

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness


  • Change from Baseline in the transition zone index (TZI) at different time points [ Time Frame: 1 month, 2 months and 3 months ] [ Designated as safety issue: No ]

    Efficacy:

    Change from Baseline in the transition zone index (TZI) at different time points (1 month, 2 months and 3 months) are evaluated in men

    Safety:

    Systemic adverse events such as difficult urination, dry mouth, dry eye, blurred vision, constipation, dizziness or general weakness



Estimated Enrollment: 200
Study Start Date: March 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study group
Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD
Study group
Other Names:
  • Tolterodine (Detrusitol) 4mg QD
  • Oxybutynin (Ditropan) ER 5mg QD
Experimental: Control group
Tolterodine (Detrusitol) 4mg QD
Drug: Detrusitol 4mg QD
Control group
Other Name: Tolterodine (Detrusitol) 4mg QD

Detailed Description:
  • Introduction:Overactive bladder (OAB) is a symptom syndrome characterized by urgency frequency with or without urgency incontinence. Usually no metabolic or anatomical disorders can be found in patients with OAB, and the condition may have a great impact on quality of life. Antimuscarinics are the first line treatment and yield a success rate of more than 70%. Urothelial dysfunction and abnormalities of sensory receptor expression or transmitter release in the suburothelial nerves might contribute to OAB which is refractory to antimuscarinics. In patients who failed current antimuscarinic treatment, intravesical botulinum toxin A (BoNT-A) injection provides an chance of improvement. Previous studies reported success rates of BoNT-A injection for OAB ranged from 60 to 80%. Intravesical treatment to inhibit abnormal receptor expression or transmitter release in the sensory nerve terminals of the suburothelial space can provide good therapeutic effects in the treatment of OAB. However, patients might develop large postvoid residual (PVR) and subsequent urinary tract infection (UTI) after BoNT-A injections, therefore, this treatment is usually left for patients who are refractory to antimuscarinic therapy. However, how to define antimuscarinic refractory OAB remains controversial. How many different types of antimuscarinics should be prescribed before we call the case failure has not been elucidated. The aim of this study is to evaluate the effect of flexibly adding-on oxybutynin ER (5mg QD) in patients with OAB who were refractory to monotherapy with the first antimuscarinic agent (tolterodine 4mg QD).
  • Methods: A total of 200 patients with refractory OAB will be included in this prospective, open label protocol. Inclusion criteria are persistent OAB symptoms (frequency urgency with/without urgency urinary incontinence) after behaviour therapy and an optimized dose of one antimuscarinic agent (Tolterodine 4mg) for at least 3 months. Patients with neurogenic diseases, untreated bladder outlet obstruction, recurrent UTI, large PVR (>150ml) will be excluded from this study. Patients will be randomized to allocate in the treatment group (receiving tolterodine 4mg QD and oxybutynin 5mg to 15mg QD) or control group (tolterodine 4mg QD) in 1:1 ratio based on the permuted block randomization code. Oxybutynin ER 5mg to 15 mg once daily will be flexibly adding-on from baseline to the third month in the treatment group, depending on patient's effectiveness and tolerability to adverse events. At the baseline, 1 and 3 months after oxybutynin ER adding-on, we will assess the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), Patient Perception of Bladder Condition (PPBC), the Urgency Severity Scale (USS) questionnaires, uroflowmetry and PVR. The therapeutic effect will be considered as successful if there was a reduction of PPBC of 2 from baseline and a reduction of USS of 1 from baseline, or the USS value is 0 at 3 months. The adverse events and tolerability of this combined therapy will also be assessed.
  • Expected Results: Compared with baseline, total IPSS, IPSS storage subscore, quality of life indexes, OABSS, USS and PPBC will be expected to significantly decrease at 1 and 3 months. PVR might be increased at 3 months after adding-on treatment. The changes of IPSS voiding subscore, peak urinary flow rate and voided volume might be increased or comparable to the control group during the follow-up. We expect at least one-third of patients can have a successful therapeutic effect without significantly increased adverse events. However, the other patients might withdraw from the study due to adverse events such as severe dry mouth, constipation, large PVR, UTI, severe difficult urination or acute urinary retention.

Adverse events should be cautiously monitored during the treatment course.

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged ≥20 years of male or female gender with OAB refractory to one antimuscarinics therapy
  • Patient or his/her legally acceptable representative has signed the written informed consent form

Exclusion Criteria:

  • Patients with untreated bladder outlet obstruction, intrinsic sphincter deficiency, pelvic organ prolapse
  • Patients with history of urethral injury or transurethral surgery for prostate or bladder
  • Patients with severe cardiopulmonary disease and such as congestive heart failure, arrhythmia, poorly controlled hypertension, not able to receive regular follow-up
  • Patients with known active urinary tract infection, urinary stone or malignancy
  • Patients have laboratory abnormalities at screening including:

    1. Aspartate aminotransferase (AST) > 3 x upper limit of normal range.
    2. Alanine aminotransferase (ALT) > 3 x upper limit of normal range.
    3. Patients have abnormal serum creatinine level > 2 x upper limit of normal range.
  • Patients with urinary retention, PVR≥250 ml
  • Patients with any other serious disease or condition considered by the investigator not suitable for entry into the trial
  • Patients participated investigational drug trial within 1 month before entering this study
  • Patients with major psychiatric illness or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01824420

Contacts
Contact: Hann-Chorng Kuo, M.D. 886-3-8561825 ext 2113 hck@tzuchi.com.tw

Locations
Taiwan
Buddhist Tzu Chi General Hospital Recruiting
Hualien, Taiwan, 970
Contact: Hann-Chorng Kuo, M.D.    886-3-8561825 ext 2113    hck@tzuchi.com.tw   
Contact: Dong-Ling Tang, Miss    886-3-8561825 ext 2117    dong_lin86@yahoo.com.tw   
Principal Investigator: Hann-Chorng Kuo, M.D.         
Sponsors and Collaborators
Buddhist Tzu Chi General Hospital
Investigators
Principal Investigator: Hann-Chorng Kuo, M.D. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University
  More Information

Publications:
Responsible Party: Hann-Chorng Kuo, Department of Urology, Buddhist Tzu Chi General Hospital
ClinicalTrials.gov Identifier: NCT01824420     History of Changes
Other Study ID Numbers: TCGHUROL008
Study First Received: April 1, 2013
Last Updated: April 3, 2014
Health Authority: Taiwan: Department of Health
Taiwan: Research Ethics Committee

Keywords provided by Buddhist Tzu Chi General Hospital:
Refractory overactive bladder syndrome
Antimuscarinic agent

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Muscarinic Antagonists
Oxybutynin
Tolterodine
Phenylpropanolamine
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Urological Agents
Therapeutic Uses
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Appetite Depressants
Anti-Obesity Agents
Central Nervous System Agents
Sympathomimetics
Nasal Decongestants
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on August 21, 2014